Default company panoramic image
1420c0d0 29b3 4a2a 8ffd 485c69dabf19

BioIncept LLC

PreImplantation Factor (PIF) reverses paralysis and regenerates nerve tissue in EAE (MS) model.13 US patents, human trials 2013. Non-toxic.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded January 1996
  • Employees 4
  • Website

Company Summary

BioIncept is planning human trials of PreImplantation Factor (PIF), a human peptide secreted by 2 cell embryos. PIF enables selective regulation of the immune system to accept the embryo while maintaining protection against disease. This selective immune control does not have the dangerous side effects of immune suppressants and is shown to reverse paralysis. PIF is targeted to treat immune and pregnancy disorders, and transplant rejection.


  • Default avatar
    Jacqueline Barnea

    Co-founder, President, and Chief Executive Officer of BioIncept, Dr. Jacqueline Barnea holds a doctorate in international business law and business administration from the University of Paris I, Panthéon-Sorbonne. Since 1989, she has focused her career on the management and commercialization of biomedical technologies with potential clinical applications.

  • Default avatar
    Eytan Barnea
    Chief Scientist

    Dr. Barnea is a double-board certified in Obstetrics and Gynecology and Reproductive Endocrinology, and a full-time clinician. He serves as Director of Obstetrics, Gynecology, and Reproduction at CAMcare Health Organization in New Jersey, which he joined in 1994. Under his tenure, the department increased eight-fold, becoming the largest such clinical department in Southern New Jersey.

  • Default avatar
    Barton O'Brien
    Board Member

    Bart has been a co-founder of two successful software companies - RSA Data Security and Calico Commerce. Bart has also been on the executive team of several other startups, including iSpheres, Sabrix and Attensity. Bart and his wife own O'Brien Estate winery in Napa Valley.

  • Default avatar
    Dennis Spink
    Board Member

    • Dennis Spink is currently an Executive Director at Oppenheimer & Co. Having spent 43 years at various Wall Street firms, including Head of Trading and a Managing Director at L.F. Rothschild, Head of Corporate Bond Trading at Wachovia Bank and Head of Corporate Bond Trading and Managing Director at Stern Agee & Leach.

  • Default avatar
    George Frank
    Board Member

    George W. Frank, Jr is currently retired after a 37 year career in the investment industry. The first 21 years were spent at Merrill Lynch. Mr. Frank moved to Smith Barney and Co. in 1986 as Manager of retail products in the Syndicate Department. He then served on the Commitment Committee for Corporate Finance, Head of Equity Capital Markets and then Global Head of Equity Institutional Sales.


  • Default avatar
    Pepper and Hamilton